0001140361-19-013312.txt : 20190821 0001140361-19-013312.hdr.sgml : 20190821 20190723160215 ACCESSION NUMBER: 0001140361-19-013312 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770701744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 820 S FRIENDSWOOD DRIVE STREET 2: SUITE 201 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 820 S FRIENDSWOOD DRIVE STREET 2: SUITE 201 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 CORRESP 1 filename1.htm
July 23, 2019

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.  20549-3628


Attn:
Ruairi Regan and Pamela Howell
   
Re:
Castle Biosciences, Inc. (the “Company”) – Request for Acceleration
 
Registration Statement on Form S-1 (File No. 333-232369)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of common shares, we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:30 p.m. Eastern Time on July 24, 2019, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the Act, we wish to advise you that, through the date hereof, we have effected the following distribution of the Company’s Preliminary Prospectus dated July 15, 2019, the Company’s Preliminary Prospectus dated July 19, 2019 and the Company’s Free Writing Prospectus dated July 19, 2019: approximately 1,330 copies to underwriters, dealers, institutions and others.

We, the undersigned, as representatives of the several underwriters, have complied and will continue to comply, and we have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.




[Signature Page Follows]

 
Very truly yours,
       
 
SVB Leerink LLC
 
Robert W. Baird & Co. Incorporated
       
 
As representatives of the several Underwriters
       
 
By:
SVB Leerink LLC
       
   
By:
/s/ Ryan Lindquist
   
Name:
Ryan Lindquist
   
Title:
Managing Director
       
       
 
By:
Robert W. Baird & Co. Incorporated
       
   
By:
/s/ Ryan Engelhardt
   
Name:
Ryan Engelhardt
   
Title:
Managing Director

[Signature Page to Acceleration Request Letter]